April 25th 2024
Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Bispecifics in MM: Future Directions in Care
Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.
Long-Term Monitoring for CRS and AEs With Bispecific Therapy
Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.
Selecting Patients for BCMA and Non-BCMA Bispecifics in Multiple Myeloma
Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.
Initial Monitoring for CRS and AEs in Patients With MM on Bispecifics
Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.
Updated Results of the MonumenTAL-1 Study in R/R MM
Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.
Available Treatment Options for Patients With R/R MM
Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.
Optimizing Treatment Strategies in Relapsed/Refractory Multiple Myeloma
A panel of experts shares insight on treatment sequencing and selection in the setting of relapsed/refractory multiple myeloma.
Frontline Treatment Regimens in the Setting of Transplant-Ineligible NDMM
Experts from Ochsner Health highlight treatment options for patients who present with transplant-ineligible newly diagnosed multiple myeloma.
Curability, Maintenance Therapy, and Unmet Needs in Multiple Myeloma
A recent Satellite Sessions program hosted by CancerNetwork® brought together experts from different Ochsner Health campuses to discuss the diversity of practices among care providers regarding patient interactions and treatment choices.
Multiple Myeloma: Addressing Financial Barriers to Bispecifics
Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.
Bispecifics in MM: mSMART Guidelines for Monitoring and Managing AEs
Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.
Pharmacists’ Perspectives on Initiating Bispecific Therapy in Multiple Myeloma
Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.
Insights from Experts at Mayo Clinic: Step-up and Treatment Dosing of Bispecifics
A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.
Treatment Approaches in Patients With Transplant-Ineligible NDMM
Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.